Fennec Pharmaceuticals Inc. FENC
10.64 USD +0.06 (+0.57%)
At closeNov 11, 2026, 4:01 PM EST
10.64 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
10.45 Day range 10.80
5.65 52-week range 13.25
- YTD
- +38.18%
- 1 year
- +34.34%
News
globenewswire.com Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the…
defenseworld.net Adherex Technologies Inc. (NASDAQ:FENC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat reports. One investment analyst…
defenseworld.net Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the…
globenewswire.com Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $16 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $16 price target.
benzinga.com B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18 B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
benzinga.com Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16 Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
zacks.com Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect? The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
seekingalpha.com Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
marketbeat.com Adherex Technologies Q2 Earnings Call Highlights Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year…
zacks.com Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
benzinga.com Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of…
globenewswire.com Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the…
defenseworld.net Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company,…
zacks.com Is the Options Market Predicting a Spike in Adherex Technologies Stock? Investors need to pay close attention to FENC stock based on the movements in the options market lately.
globenewswire.com Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced…
globenewswire.com Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced…
globenewswire.com Fennec Announces Results of Annual Meeting RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy…
marketbeat.com Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside…
benzinga.com HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $16.
globenewswire.com Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting ~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
globenewswire.com Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced…
seekingalpha.com Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
marketbeat.com Adherex Technologies Q1 Earnings Call Highlights Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow…
benzinga.com Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript 
zacks.com Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.- benzinga.com Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin ~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~~ This New Study and Other Independent,…
benzinga.com Fennec Pharmaceuticals Q4 GAAP EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over…- benzinga.com Earnings Scheduled For March 24, 2026
benzinga.com Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.- benzinga.com Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033 Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the…
- benzinga.com Fennec Pharma Backs Real-World Study Of PEDMARK To Protect Hearing In Cancer Patients Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that the Tampa General Hospital (TGH) Cancer Institute is initiating a study evaluating the…
- benzinga.com Piper Sandler Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $18 Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.
benzinga.com Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Fennec Pharmaceuticals Released Topline Results From Phase 2/3 STS-J01 Trial Of Pedmark (Sodium Thiosulfate Injection) For The Reduction Of Cisplatin-induced Ototoxicity In Pediatric And Adolescent And Young Adult Patients With Non-metastatic Solid Tumors In Japan Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of…
benzinga.com Reported Earlier, Fennec Pharmaceuticals Prices Offering Of 4,666,667 Common Shares At $7.50 Per Share For ~$35M In Gross Proceeds Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness and the remaining net proceeds, if any, for working capital and general corporate purposes.- benzinga.com Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 90.48 percent increase over losses of $(0.21) per share from…
- benzinga.com Fennec Pharmaceuticals Plans To Launch Common Stock Offering; Terms Not Disclosed Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $13 price target.
- benzinga.com Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $14 Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $14.
- benzinga.com Fennec Pharmaceuticals Q2 EPS $(0.11) Misses $(0.04) Estimate, Sales $9.65M Beat $9.52M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.04) by 205.56 percent. This is a 45 percent increase over losses…
- benzinga.com Earnings Scheduled For August 14, 2025
- benzinga.com Fennec Pharmaceuticals Earnings Preview
- benzinga.com HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and maintains $13 price target.
- benzinga.com Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $13 Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $12 to $13.
- benzinga.com Fennec Pharmaceuticals Q1 EPS $(0.04) Beats $(0.09) Estimate, Sales $8.75M Beat $8.18M Estimate Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 109.76 percent decrease over…
- benzinga.com Earnings Scheduled For May 13, 2025